DIRS.INFO The most relevant business & tech news

☆ Cathie Wood says her 'volatile' ARK Innovation fund shouldn't be a 'huge slice of any portfolio'
▼ + stars: | 2024-11-15 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange (NYSE) in New York City, February 27, 2023. Cathie Wood is defending her underperforming ARK Innovation exchange traded fund following a rocky stretch. Since then, the fund has underperformed, fueling skepticism over the Ark Invest CEO's investment strategies. She called out the multiomics life sciences and health care sectors as the biggest drag on the fund. "We think we're a very good complement to the broad-based benchmarks out there, because we don't look anything like them," she said of her fund.

Persons: Cathie Wood, CNBC's, Wood Organizations: Ark Invest, CNBC, New York Stock Exchange, Innovation, Ark, Intellia Locations: New York City

☆ A 68-year-old cofounded a biotech business instead of retiring. He's not getting paid for his work but values staying 'mentally engaged.'
▼ + stars: | 2024-08-08 | by ( John Towfighi | ) www.businessinsider.com time to read: +5 min

Two years ago, when he was 68, that opportunity arose: McCaman cofounded Orion Therapeutics, a small company developing new ways for RNA medicine to reach specific areas of the human body. AdvertisementMcCaman, now 70, is the vice president and chief strategy officer at Orion Therapeutics. McCaman is passionate about staying engaged with his interests and said remote work has enabled him to extend his career. McCaman and Fischer launched Orion with Deidra Mountain, a University of Tennessee professor, and Jennifer Zachry, a graduate student. Are you a baby boomer who founded a small business?

Persons: —, Michael McCaman, McCaman, It's, Davis, Intellia, Trey Fischer, Fischer, Jennifer Zachry, there's, John Deere Organizations: Service, Orion Therapeutics, Business, University of California San, University of California, Intellia Therapeutics, University of Tennessee, Orion, University of Tennessee Research Foundation, Launch Locations: Frederick , Maryland, Knoxville , Tennessee, University of California San Diego, California, Lonza, Maryland, Launch Tennessee

☆ Stocks held by ARK Invest's flagship innovation fund have seen huge losses. Here are the fund's 10 biggest losers.
▼ + stars: | 2024-05-27 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Ark Invest's flagship innovation ETF, which trades under the ticker symbol "ARKK," has seen massive losses since it peaked in February 2021. Here are the 10 biggest losers held in the ARKK ETF, according to data from Cathie's Ark. Pacific BiosciencesMarkets InsiderARKK average cost basis: $19.84Current price: $1.88% Change: -90.2%2. Teladoc HealthMarkets InsiderARKK average cost basis: $163.91Current price: $11.43% Change: -93.0%Advertisement1. Ginkgo BioworksMarkets InsiderARKK average cost basis: $9.99Current price: $0.66% Change: -93.4%

Persons: —, It's, Wood, Tesla Organizations: ARK, Service, Invest, Nasdaq, Intellia Therapeutics, UiPath, Roku, Verve Therapeutics, Unity Technologies, Genomics, Pacific Biosciences, Teladoc

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

☆ 4 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-02-17 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

A hotter-than-expected consumer price index on Tuesday sent stocks reeling, with the Dow posting its biggest drop in a year. Stocks bounced back over the next two days, helped by a softer retail sales report , only to slump again on Friday's hot producer price index for January. As we said this week, we're not overly concerned with the hotter-than-expected inflationary readings. Earnings season picks back up for the Club next week, with four holdings set to report quarterly results. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Wall, Stocks, we're, Palo, Fortinet, BCH's Bausch, Management doesn't, Dana, Bausch, Dr Pepper, Diana Shipping, Jim Cramer's, Jim Cramer, Jim, Jensen Huang, Walid Berrazeg Organizations: Dow Jones Industrial, Nasdaq, Dow, Federal Reserve, Club, Palo Alto, Palo, billings, Nvidia, Amazon, Microsoft, Bausch Health, Coterra Energy, Management, NYSE, Walmart, Axsome Therapeutics, Barclays Bank, Armstrong World Industries, Ceragon Networks, Tri Pointe Homes, Dana Incorporated, DigitalBridge, Oil States International, Systems, Allegion, CenterPoint Energy, Equitrans Midstream Corporation, Expeditors International of Washington, Alto Networks, SolarEdge Technologies, Enovix Corporation, Caesars Entertainment, Diamondback Energy, Toll, Ternium S.A, Celanese Corp, Chesapeake Energy, CVR Energy, Reserve, Vertiv Holdings Co, Properties Trust, Devices, HSBC Holdings plc, HSBC, Lomb, Sinclair Corporation, Pagaya Technologies, Gibraltar Industries, Garmin, NVIDIA, Rivian Automotive, Sunnova Energy International, Bros, Apache, Oil, Suncor Energy, Co, FNF, Sciences, Coeur D'Alene Mines, Trip.com, Joby Aviation, Resources, Alamos, Jackson, Nutrien, NTR, Pan, Sm Energy Company, Health, Newmont, Nikola Corporation, Cheniere Energy, Fiverr, Natural Resources, Point Credit, Lantheus Holdings, Builders, Grab Holdings, NICE, Dominion Energy, Harmony Biosciences Holdings, Teck Resources Limited, Intellia Therapeutics, Energy, Booking Holdings, Intuit, Semiconductor, Nation Entertainment, Vale S.A, Rocket Companies, Warner Bros ., AerCap Holdings, Natural Holdings, Calumet Specialty Products Partners, Frontier Communications, Jim Cramer's Charitable, CNBC, Lightrocket, Getty Locations: billings, Palo Alto, China, Xifaxan, Tri Pointe, Avista, Gibraltar, Coeur D'Alene, Pan American, Teck, Vale

☆ Elon Musk is about to find out if ultimatums really work
▼ + stars: | 2024-01-18 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at the ultimatum Elon Musk gave Tesla's board amid a critical time for the company. The big storyElon's ultimatumREUTERS/Steve NesiusUltimatums rarely work in relationships, but what about between CEOs and the massive companies they run? Elon Musk is about to find out. Musk, who has roughly a 13% stake in the EV maker, said if his request isn't met, he'll "prefer to build products outside of Tesla." Meanwhile, Ross Gerber, a longtime Tesla bull, said it's "absurd" to think Musk doesn't already have control over Tesla and described his request as "blackmailing the Tesla shareholders."

Persons: —, Antony Blinken, Elon Musk, Steve Nesius Ultimatums, Elon, isn't, didn't, Wedbush's Dan Ives, Musk's, Ross Gerber, Tesla, Dow Jones, George Glover, That's, cowering, Caspar Benson, Jamie Dimon, dory, Trump, Ray Dalio, Biden, Evan Spiegel's, Hokyoung Kim, They've, Kristen Stewart, Christopher Nolan, Maite Alberdi, Celine Song, Eugene Lee Yang, Dave Bautista, Kevin Costner, Estelle, AA Milne, Jay Chou, Jennifer Ortakales Dawkins Organizations: Service, Boeing, Business, Tesla, EV, Apple, Microsoft, Nvidia, Getty, Intellia Therapeutics, Shoals Technologies, JPMorgan, Biden, Bridgewater Associates, Trump, Alliance, Helicopter, BI, Sundance, Northern Trust Locations: Switzerland, Tesla, Northern

☆ On tap this week: Jobs report plus 10 key earnings. Here's what we want to see
▼ + stars: | 2023-07-29 | by ( Zev Fima | ) www.cnbc.com time to read: +18 min

All three major averages advanced for the week, powered by strong mega-cap earnings and favorable inflation data. Looking to next week, earnings season enters its second half with the last of our mega-caps — Apple (AAPL) and Amazon (AMZN) — set to report on Thursday. We'll get a better read on the employment picture on Wednesday with the ADP report and then, more importantly, on Friday's nonfarm payrolls report for July. Thursday after the close brings us to the main events of the week: Earnings from Apple and Amazon. For those looking to review first quarter performance ahead of these releases, be sure to keep our first-quarter earnings report card handy.

Persons: We'll, that's, Stanley Black, Decker, Emerson, Bausch, Leggett, Platt, SIRI, Ares, COLM, PERI, Kraft Heinz, Phillips, Ferrari N.V, Johnson, Robinson, COOK, BUD, Kellogg, Papa, Pitney Bowes, Parker, Trimble, Ziff Davis, Nonfarm, Jim Cramer's, Jim Cramer, Jim, Apple Tim Cook, Kevin Dietsch Organizations: Nasdaq, Dow, Federal Reserve, Federal, ISM Manufacturing, Services PMI, Investors, Caterpillar, Devices, Starbucks, Natural Resources, AMD, Management, Emerson Electric and, Humana, Bausch Health, Apple, Microsoft, Resource Partners, AerCap Holdings, CNA Financial Corp, CNA, Apellis Pharmaceuticals, Bank, SJW, Hutchison China MediTech, Camtek Ltd, Silvercrest Asset Management, Loews Corp, Oxford Lane Capital Corp, Banco Santander, Silicom Ltd, SuperCom Ltd, Arista Networks, Avis Budget Group, Diamondback Energy, Lattice Semiconductor Corp, Republic Services, Yum China Holdings, Western Digital Corp, Power Systems, Tenet Healthcare Corp, Vornado Realty, BioMarin Pharmaceutical, PetMed, SBA Communications Corporation, Brixmor, Snack Foods Corp, Cushman & Wakefield, Sanmina Corporation, TFI, PMI, Cruise Line Holdings Ltd, Uber Technologies, Pfizer, Enterprise Products Partners, Merck, JetBlue Airways Corporation, Allegro MicroSystems, Altria, SunPower Corp, SiriusXM Holdings, Molson Coors Beverage, Marriott International, Toyota Motor Corp, BP, SYSCO Corp, Marathon Petroleum Corp, Ares Management, Equitrans Midstream Corporation, Game Technology, Illinois Tool, IDEXX Laboratories, Rockwell Automation, Packaging International Corp, Gartner, Zebra Technologies Corp, IQVIA Holdings, Oshkosh Corporation, Leidos Holdings, Eaton Corp, yte Corp, Lear Corp, Starbucks Corp, Devon Energy Corp, SolarEdge Technologies, Lumen Technologies, Virgin Galactic Holdings, Caesars Entertainment, VF Corp, Sciences Corp, Paycom, Vertex Pharmaceuticals, Suncor Energy, Holdings, Chesapeake Energy Corp, Boston Properties, American International Group, AIG, Allstate Corp, Aspen Technology, Electronic Arts, EA, Flowserve Corporation, Denny's, Corp, Prudential Financial, Store, Ternium S.A, Vimeo, Emerson, Lomb, CVS Health, Generac Holdings, Cameco Corp, Perion Network Ltd, Builders, Carlyle Group, Scorpio, Teva Pharmaceutical Industries, Ltd, Rithm Capital Corp, AeroSystems Holdings, Vertiv Holdings Co, Johnson Controls, CDW Corp, DuPont, Brands Holdings, Scotts Miracle, Gro, SMG, Brands, Allegheny Technologies, AmerisourceBergen Corporation, ABC, Real Estate Corporation, Adient plc, Editas, Garmin Ltd, WWE, Bunge Ltd, Criteo S.A, PayPal, QUALCOMM, Occidental Petroleum Corp, Apache Corp, Albemarle Corp, MGM Resorts International, MGM, Marathon Oil Corp, Joby Aviation, Industrial, CF Industries Holdings, Goodyear Tire &, Realty ome Corp, Metlife, Pacific Biosciences of, Rush Street Interactive, Zillow, JFrog Ltd, Herbalife Nutrition Ltd, Simon Property Group, McKesson Corp, Storage, Cerus Corporation, GXO Logistics, MAX Holdings, Health, Anheuser, Busch InBev, Warner Bros ., Cheniere Energy, ConocoPhillips, Hasbro, CIGNA Corp, Lantheus Holdings, Regeneron Pharmaceuticals, Fiverr International, Air Products & Chemicals, TopBuild Corp, EPAM Systems, Lightspeed Commerce, Aurinia Pharmaceuticals, Cummins, CMI, Slair Corporation, Starwood Property Trust, Vulcan, Alnylam Pharmaceuticals, New Energy Corp, Cedar Fair Entertainment, Intellia Therapeutics, Lending, Privia Health, Dickinson, Chimera Investment, CIM, Hyatt Hotels Corp, Lion Electric, LEV, Deluxe Corp, Murphy Oil Corp, PBF Energy, Papa John's, Targa Resources Corp, Wix.com Ltd, Apollo Global Management, LLC, Butterfly, Sempra Energy, Aptiv PLC, Brookfield Infrastructure Partners, Canada Goose Holdings, Hannifin Corporation, WESCO International, WCC, Arrow Electronics, Constellation Energy Group, Midstream Partners, Coinbase, Petroleo Brasileiro SA Petrobras, Gilead Sciences, Opendoor Technologies, Booking Holdings, Atlassian Corporation, International, Redfin Corporation, Motorola Solutions, Monster Beverage Corporation, Consolidated Edison, Rocket Companies, Apple Hospitality, Cirrus, Resources, Universal Display Corporation, Chesapeake Utilities Corp, Social, Defense, Security Solutions, Post Holdings, Tandem Diabetes Care, Nikola Corporation, Magna International, Dominion Energy, ACM Research, Frontier Communications, Brookfield Renewable Partners, inTEST Corporation, American Pipeline, TELUS International, XPO Logistics, Fluor Corp, Gray Television, Cboe, LyondellBasell Industries, Twist Bioscience, Global, Jim Cramer's Charitable, CNBC, Allen & Company Sun Valley, Getty Locations: U.S, China, India, Oxford, Chile, Illinois, Columbia, Pacific, Pacific Biosciences of California, Southern, PBI, Gilead, Sun Valley , Idaho

JPMorgan refreshed its list of top stock picks heading into April, including a bank stock that's had a rocky start to the year. To kick off the month of April, JPMorgan added two new names to its focus list: VICI Properties and Regions Financial. The other new name on the list, Regions Financial , has declined 15% in 2023. GM shares are up 6.2% in 2023. JPMorgan removed two names from its list: Intellia Therapeutics and Jones Lang LaSalle .

☆ Analysts love these AI stocks with big upside potential to play the ChatGPT-driven artificial intelligence craze
▼ + stars: | 2023-02-07 | by ( Tanaya Macheel | ) www.cnbc.com time to read: +2 min

Each name in the list that follows has potential upside of about 35% or more, buy ratings from at least 60% of analysts and at least 10 analysts covering the stock. It has about 39% potential upside and buy ratings from almost 62% of the analysts covering it. Intellia Therapeutics , a company focused on gene-editing treatments, has upside potential of about 140% and buy ratings from 72% of its 27 analysts. Denali Therapeutics , which is focused on defeating neurodegenerative diseases, is close behind, with upside potential of 104% and buy ratings from almost 89% of its 18 analysts. Karuna Therapeutics , which specializes in schizophrenia treatments, holds the largest percentage of buy ratings, coming from 95% of its 20 analysts.

☆ These innovation stocks owned by Cathie Wood have double-digit upside, according to analysts
▼ + stars: | 2023-02-06 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Cathie Wood just scored her best month ever as her innovation stocks staged a big comeback, and some of her darlings still have double-digit upside ahead, according to Wall Street analysts. Wood's flagship Ark Innovation ETF (ARKK) jumped 27.8% in January alone, notching its strongest month since its inception in 2014 . We looked at companies with at least five analysts covering them, and these names below all have more than 10% upside in the next 12 months, according to FactSet. Wall Street analysts are most bullish on Ginkgo Bioworks , seeing the stock rally more than 140% in the next 12 months. Other biotech names in the space that analysts love are Verve Therapeutics , CRISPR Therapeutics , Beam Therapeutics and Twist Bioscience.

☆ A tiny biotech just suffered a safety scare in a gene-editing trial, raising 3 big questions for the entire CRISPR field
▼ + stars: | 2023-01-06 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

The biotech halted the trial while it investigates the case, which may impact other CRISPR companies. The small biotech company Graphite Bio said Thursday afternoon that it paused a study testing an experimental gene-editing therapy after the first treated patient suffered a serious side effect. The safety scare raises more questions than answers as Graphite's scientists investigate what exactly may have caused the side effect. Lehrer said it's too early to say whether this safety scare could have implications for the broader gene-editing field. Its next-closest product, a gene-editing therapy for beta-thalassemia, isn't expected to start initial human testing until 2024 at the earliest.

☆ Here are Goldman's best stock option trades for 2023
▼ + stars: | 2022-12-07 | by ( Jesse Pound | ) www.cnbc.com time to read: +3 min

The firm calculated the single stock options with the most upside by comparing the price of an at-the-money call that expires in Jan. 2024 with the hypothetical return if the stock reaches the price target of Goldman's analyst. Call options serve as bets that a stock price will rise above a set strike price during the life of the contract. One benefit of using options is that, if the stock falls, the investors lose only the premium paid for the option. If it continues to climb to Goldman's price target, the call option could deliver a return of nearly 300%, the firm said. A put option is effectively the inverse of a call option and serves as a bet that a stock will fall below a set strike price.

☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.

☆ See the 20-slide presentation this biotech startup used to raise $75 million for a way to treat blindness with CRISPR
▼ + stars: | 2022-09-14 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +2 min

About a year ago, the startup secured an exclusive deal with CRISPR gene-editing leader Intellia. SparingVision, a Paris-based startup, just raised $75 million to advance a suite of gene-therapy and gene-editing programs to treat eye diseases. The company plans to use the funds to enter the clinic with its first gene-therapy program. The cash will also help advance SPVN50, SparingVision's first gene-editing program. The program came out of a research collaboration SparingVision struck with Intellia Therapeutics, a CRISPR gene-editing leader, last year.

Search resuls for: "Intellia Therapeutics"

15 mentions found